Companies › ALZN

Alzamend Neuro Inc (ALZN)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001677077 · EDGAR filings · Updated 2026-07-22

Alzamend Neuro Inc (ALZN) has reported institutional ownership of 2.4%, with 12 institutional managers holding positions valued at $122.4K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (1)

• 2026-07-22 — Annual report (10-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-21 — Current report (8-K) filed
• 2026-04-17 — Current report (8-K) filed
• 2026-04-16 — Insider transaction reported (Form 4)
• 2026-03-20 — Current report (8-K) filed
• 2026-03-11 — Quarterly report (10-Q) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Alzamend Neuro Inc has 12 institutional holders and institutional ownership of 2.4%.

Insider activity

Insiders reported 36 transactions (0 buys, 27 sells) across 3 reporting insiders, with a net reported value of −$2.23M.

Data flags from SEC filings

Related companies

Sunshine Biopharma Inc (SBFM) · AZITRA INC (AZTR) · ZOMEDICA CORP COM (ZOMDF) · Bio Green Med Solution Inc (BGMS) · BLUEJAY DIAGNOSTICS INC (BJDX) · Enveric Biosciences Inc (ENVB)